Clinical expertise
Drug trials from phase I to IV, medical device investigations and IVD performance studies. This page is a taste of what our core CRA team has done. What we can cover goes far beyond it.
People who have done it before
In an urgent or exacting study it matters that the people on it have done similar work before. We match every consultant to the product, the therapy area and the phase of your study, so you spend less time vetting candidates and less time training them. What follows is a taste, not the full list. It shows only what the people in our core CRA team have done themselves. With our wider network of consultants we cover far more therapy areas, countries and roles than fit on one page.
Medicines, devices and diagnostics
The rules differ for each, and so does the work at the site. We do all three, and the studies where two of them meet.
Medicinal products
Phase I to IV trials, including first-in-human and paediatric studies. We prepare the application through CTIS under the EU Clinical Trials Regulation, answer the requests for information and keep the dossier current through modifications.
Medical devices
Clinical investigations under the MDR and ISO 14155, before and after CE marking: joint implants, stents and stent-grafts, transcatheter heart valves, neuromodulation, insulin pumps and robotic surgery.
In vitro diagnostics
Performance studies under the IVDR, including companion diagnostics that run alongside an oncology drug trial. In 2026 this has been our busiest area for submissions.
Combination studies
A drug trial with a companion diagnostic, a drug-coated device, a medicine given through a device. Two sets of rules apply at once. We plan both routes together so that neither holds up the other.
Planning a device or IVD study? Medical device and IVD studies in Finland explains the approval route and what we take care of.
Therapy areas and indications
The indications below come from studies our core CRA team have monitored, started up or managed. They are examples, not limits.
Oncology and haematology
Breast, prostate, lung and ovarian cancer, melanoma, hepatocellular carcinoma and other solid tumours. Multiple myeloma, MDS, CMML and AML. First-in-human studies and acute graft-versus-host disease.
Cardiovascular
Heart failure, coronary bypass surgery, pulmonary arterial hypertension and cardiogenic shock. Device studies with coronary stents, drug-eluting balloons, transcatheter aortic and mitral valves, aortic stent-grafts, pacemakers and heart monitors.
Neurology and psychiatry
Major depressive disorder, schizophrenia, multiple sclerosis, restless legs syndrome and amyloidosis. Neuromodulation studies: deep brain stimulation, and vagus nerve stimulation in epilepsy.
Gastroenterology and hepatology
Ulcerative colitis, Crohn’s disease and eosinophilic oesophagitis. Cirrhosis, hepatic impairment studies, NASH and primary biliary cholangitis.
Paediatrics
Paediatric oncology, including acute lymphoblastic leukaemia. Insulin pump studies in children with type 1 diabetes, kidney transplantation in highly sensitised children, paediatric cardiac surgery and rare neurological disorders.
Vaccines and infectious diseases
HPV, RSV, influenza and hepatitis vaccines. Our CRAs have worked on some of the largest vaccine trials run in Finland, where a small error repeated across thousands of participants becomes an expensive one.
Metabolic, endocrine and rare diseases
Type 1 and type 2 diabetes, Graves’ disease and hyperphosphataemia. Rare diseases such as Fabry disease and alpha-mannosidosis.
Immunology, respiratory and skin
Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. COPD and nasal polyps. Dermatology studies.
Surgery, kidney and women’s health
Hip and shoulder replacement, robotic surgery and dental light therapy. Kidney transplantation. Contraception, uterine fibroids and pregnancy safety studies.
Is your indication missing? Ask us anyway. This page covers our core CRA team only, and our consultant network reaches much further. When a study needs knowledge nobody has yet, we train the consultant for it together with you before the work starts. A RecQ CRA works alongside the investigator as an equal partner, in the most demanding studies too.
2026 Monitoring Stats
Status: Q3 2026, core CRA team only. We update these figures every quarter.
By type: 84 monitoring visits, 32 site selection and qualification visits, 21 initiation visits, 11 close-out visits and 2 others. Countries: Finland, Germany, Denmark, Sweden, Austria, the Netherlands, Belgium, Switzerland, the United Kingdom and Türkiye.
2026 Submission Stats
Status: Q3 2026, core CRA team only. So far this year we have prepared or filed more than 40 submissions to authorities and ethics committees, for 12 studies in five countries.
Quality that stands up to inspection
Monitoring is only worth paying for if the data holds when an inspector opens the file. This is the background our team leads bring to your study.
- Studies we have monitored have been through inspections by the FDA, BfArM and Fimea.
- Rekaut Naderipour, who leads the team, is CRA of the Year 2023 (Pharmaca).
- ISO 14155 certification for medical device investigations, alongside ICH GCP.
- We teach GCP as well as follow it: alongside his work as Study Manager and CRA, Rekaut is a GCP trainer and took part in translating the current GCP guideline into Finnish.
- Daily work in Medidata Rave, Oracle InForm and eClinicalOS, under your SOPs or ours.
Where we work
Our own team covers Finland, Sweden, Norway, Denmark, Germany, the Netherlands, Switzerland, Austria and Estonia. Our CRAs have also monitored in the United Kingdom and France, and for other regions we bring in consultant CRAs from our wider network.
Roles we supply
- CRA and Senior CRA
- Study Start-Up Specialist
- Study Coordinator
- Study Nurse
- Project Manager
- Study Manager
How a study runs with us in practice: Clinical trial monitoring and CRA services in Finland
Does your study sound like one of these?
Tell us the indication and the phase. We reply by the next working day.